Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
NDC API
0
VMF
0
FDF
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1-propanesulfonamide, N-(cis-3-(methyl-7h-pyrrolo(2,3-d)pyrimidin-4-ylamino)cyclobutyl)-
2. Abrocitinib
3. N-(cis-3-(methyl(7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-1-propanesulfonamide
4. N-(cis-3-(methyl(7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide
5. Pf-04965842
1. Abrocitinib
2. 1622902-68-4
3. Pf-04965842
4. Cibinqo
5. Abrocitinib [usan]
6. 73sm5sf3or
7. Chembl4101725
8. N-[3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide
9. N-{cis-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide
10. 1-propanesulfonamide, N-(cis-3-(methyl-7h-pyrrolo(2,3-d)pyrimidin-4-ylamino)cyclobutyl)-
11. N-(3-(methyl(7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide, Cis-
12. N-(cis-3-(methyl(7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide
13. N-[cis-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)cyclobutyl]-1-propanesulfonamide
14. Unii-73sm5sf3or
15. D7d
16. N-((1s,3s)-3-(methyl(7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide
17. N-((1s,3s)-3-(methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide
18. Abrocitinib [inn]
19. Abrocitinib [jan]
20. Abrocitinib (jan/usan)
21. Abrocitinib [who-dd]
22. Gtpl9991
23. Chembl3655081
24. Schembl15970412
25. Schembl15970413
26. Pf-04965842(abrocitinib)
27. Bdbm159748
28. Dtxsid301126581
29. Pf-04965842 (abrocitinib)
30. Bcp30441
31. Ex-a3037
32. Xpc90268
33. Ac8575
34. Bdbm50243847
35. Mfcd30187577
36. S8765
37. Zb1566
38. Zinc261115849
39. Db14973
40. Sb18849
41. Compound 25 [pmid: 29298069]
42. Ncgc00601823-02
43. Ac-36318
44. As-84437
45. Sy248874
46. Hy-107429
47. Cs-0028460
48. Pf04965842
49. D11400
50. Us9035074, 2
51. A936574
52. Pf-04965842, >=98% (hplc)
53. Pf-04965842pf-04965842
54. Pf-04965842; Pf 04965842; Pf04965842
55. N-(cis-3-(methyl(7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-1-propanesulfonamide
56. N-(cis-3-(methyl(7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide
57. Abrocitinib;n-[cis-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)cyclobutyl]-1-propanesulfonamide
Molecular Weight | 323.42 g/mol |
---|---|
Molecular Formula | C14H21N5O2S |
XLogP3 | 1.7 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 6 |
Exact Mass | 323.14159610 g/mol |
Monoisotopic Mass | 323.14159610 g/mol |
Topological Polar Surface Area | 99.4 Ų |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 474 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
D11AH
D - Dermatologicals
D11 - Other dermatological preparations
D11A - Other dermatological preparations
D11AH - Agents for dermatitis, excluding corticosteroids
D11AH08 - Abrocitinib
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38879
Submission : 2023-09-15
Status : Active
Type : II
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39291
Submission : 2023-12-27
Status : Active
Type : II
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Abrocitinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Abrocitinib, including repackagers and relabelers. The FDA regulates Abrocitinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Abrocitinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Abrocitinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Abrocitinib supplier is an individual or a company that provides Abrocitinib active pharmaceutical ingredient (API) or Abrocitinib finished formulations upon request. The Abrocitinib suppliers may include Abrocitinib API manufacturers, exporters, distributors and traders.
click here to find a list of Abrocitinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Abrocitinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Abrocitinib active pharmaceutical ingredient (API) in detail. Different forms of Abrocitinib DMFs exist exist since differing nations have different regulations, such as Abrocitinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Abrocitinib DMF submitted to regulatory agencies in the US is known as a USDMF. Abrocitinib USDMF includes data on Abrocitinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Abrocitinib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Abrocitinib suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Abrocitinib Drug Master File in Korea (Abrocitinib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Abrocitinib. The MFDS reviews the Abrocitinib KDMF as part of the drug registration process and uses the information provided in the Abrocitinib KDMF to evaluate the safety and efficacy of the drug.
After submitting a Abrocitinib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Abrocitinib API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Abrocitinib suppliers with KDMF on PharmaCompass.
Abrocitinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Abrocitinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Abrocitinib GMP manufacturer or Abrocitinib GMP API supplier for your needs.
A Abrocitinib CoA (Certificate of Analysis) is a formal document that attests to Abrocitinib's compliance with Abrocitinib specifications and serves as a tool for batch-level quality control.
Abrocitinib CoA mostly includes findings from lab analyses of a specific batch. For each Abrocitinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Abrocitinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Abrocitinib EP), Abrocitinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Abrocitinib USP).
LOOKING FOR A SUPPLIER?